September 11, 2025Modern RheumatologyOpen Access

Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database

View Full Paper

Ask AI

Bookmark

Of the 14,522 patients with systemic sclerosis, 4.3% received biologics, indicating a notable adherence to evolving treatment guidelines.
Rituximab use grew significantly, with 51.8% of patients with systemic sclerosis-associated interstitial lung disease receiving it, showing a trend towards recommended therapies.
Utilization of small-molecule drugs like nintedanib and mycophenolate mofetil reflects gradual alignment with the EULAR guidelines in recent years.
Assessment was conducted using a Japanese hospital claims database from 2020 to 2023, highlighting treatment trends in SSc and SSc-ILD.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Analysis reveals increased adoption of EULAR-recommended biologics and small-molecule drugs in patients with systemic sclerosis and interstitial lung disease.

Cite This Study

Funatogawa et al. (2025) studied this question.

synapsesocial.com/papers/68d413ff713b0b5dfea6203d https://doi.org/10.1093/mr/roaf082

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals increased adoption of EULAR-recommended biologics and small-molecule drugs in patients with systemic sclerosis and interstitial lung disease.

Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database

Key Points

Discussion

Implication

Cite This Study

Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider